Publications by authors named "M Garzarolli"
Aim: ImmunoCobiVem investigated whether a planned switch to atezolizumab after achieving tumour control during run-in with vemurafenib + cobimetinib improves progression-free survival (PFS) and overall survival (OS) compared to continuous targeted therapy (TT) in patients with previously untreated advanced BRAF-mutated melanoma.
Methods: In this multicenter phase 2 study, patients received vemurafenib plus cobimetinib. After 3months, patients without progressive disease (PD) were randomly assigned (1:1) to continue vemurafenib + cobimetinib (Arm A) or switch to atezolizumab (Arm B) until first documented PD (PD1).
Background: Merkel cell carcinoma (MCC) is an immunogenic but aggressive skin cancer. Even after complete resection and radiation, relapse rates are high. PD-1 and PD-L1 checkpoint inhibitors showed clinical benefit in advanced MCC.
View Article and Find Full Text PDFBackground: Tebentafusp has recently been approved for the treatment of metastatic uveal melanoma (mUM) after proving to have survival benefits in a first-line setting.
Patients And Methods: This retrospective, multicenter study analyzed the outcomes and safety of tebentafusp therapy in 78 patients with mUM.
Results: Patients treated with tebentafusp had a median PFS of 3 months (95% CI 2.
Background: Immune checkpoint inhibitors (ICI) have emerged as a successful treatment option for diverse cancer entities. However, ICI therapy can be associated with immune-related adverse events (irAE) that can affect any organ system. These side effects can be severe, irreversible and sometimes even fatal.
View Article and Find Full Text PDFArticle Synopsis
- This study focused on advanced melanoma patients who developed brain metastases and how their treatment type influenced these outcomes.
- A total of 1,704 patients were analyzed, showing that those treated with BRAF+MEK therapy had a higher incidence of brain metastases compared to those receiving PD-1 therapies after 24 months.
- Findings indicated that the type of first-line therapy, along with tumor stage and patient age, were important factors affecting brain metastasis-free survival and overall survival in BRAF-positive melanoma patients.